CTKBCytek Biosciences, Inc.
$5.37+42% 1Y
$5.37
$3.3652 weeks$6.09
The financials
Cytek Biosciences, Inc. by the numbers
Cytek Biosciences, Inc. (CTKB) reported revenue of $48M in Q2 2026 (quarter ended Jun 30, 2026), up 5.6% from the same quarter a year earlier. That came with a gross margin of 59% and net loss of $12M. For the full year FY2025, revenue was $201M (+0.5% year on year) and net income −$67M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $48M | $46M | +5.6% |
| Gross profit | $28M | $24M | +19% |
| Operating income | −$11M | −$11M | n/a |
| Net income | −$12M | −$5.6M | n/a |
| Diluted EPS | −$0.09 | −$0.04 | n/a |